We are very pleased to learn that the ipilimumab plus nivolumab combination has been endorsed for use by the National Institute for Health and Care Excellence (NICE) for poor- and intermediate-risk advanced renal cell carcinoma (RCC). The treatment will be made immediately available to patients in England via the Cancer Drugs Fund.

The availability of this new treatment option heralds an innovative change in the treatment of advanced RCC, being the first approval of a combination of immunotherapy drugs for the treatment of RCC patients in the first-line.

NICE’s decision is based on data from the phase 3 CheckMate 214 study, which enrolled 1096 patients. This study was stopped early due to outstanding survival results versus sunitinib, the current standard of care in the first-line. In CheckMate 214 there was a 37% decreased risk of death in intermediate- and poor-risk patients, as well as an objective response rate of 42% and complete response rate of 9%.

“Today’s decision is of importance to advanced kidney cancer patients, who may now have access to more treatment options,” said Rose Woodward, Co-founder of KCSN. “Kidney cancer is a devastating disease and at the most advanced stage prognosis is poor. Having access to this combination therapy on the NHS is therefore an important new addition and a vital step in our fight to extend survival.”

KCSN would like to thank all those patients who contributed to the ipilimumab/nivolumab appraisal, especially Alison Fielding who attended the EMA appeal meeting to represent the views and opinions of the wider kidney cancer community and helped to reverse their decision to eventually grant marketing authorisation for this novel treatment – a BIG thank you!

We would also like to thank all the clinicians who fought so hard for access to this innovative new treatment on behalf of their patients. Special thanks goes out to the oncologists who submitted expert clinical opinions at the NICE appraisal meeting, and who highlighted the value of the combination in improving survival for people with advanced kidney cancer – we are STRONGER TOGETHER!

Read more in PharmaTimes here

Read more in Hospital Healthcare Europe here

Read more in The Pharma Letter here

Read more in Medical Xpress here